Loading...
Loading...
ALLK| Name | Value |
|---|---|
| Revenues | 10.8M |
| Cost of Revenue | 1.5M |
| Gross Profit | 9.2M |
| Operating Expense | 63.4M |
| Operating I/L | -65.0M |
| Other Income/Expense | 2.4M |
| Interest Income | 2.4M |
| Pretax | -62.6M |
| Income Tax Expense | 6.8M |
| Net Income/Loss | -62.6M |
Allakos Inc. is a clinical stage biopharmaceutical company specializing in developing therapeutics targeting immunomodulatory receptors on immune effector cells for allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody, lirentelimab (AK002), is in Phase III and Phase II/III studies for the treatment of eosinophilic gastritis, eosinophilic duodenitis, and eosinophilic esophagitis. Additionally, it is being developed for atopic dermatitis, chronic spontaneous urticaria, mast cell gastrointestinal disease, severe allergic conjunctivitis, and indolent systemic mastocytosis. Allakos Inc. generates revenue through the development and potential commercialization of these therapeutic products.
